Low Birth Weight, Preterm Birth, Small for Gestational Age at Delivery
Conditions
Keywords
Preterm Birth, Low Birth Weight, Small for Gestational Age, Small Vulnerable Newborn
Brief summary
The aim of the DenBalo study is to apply integrated multi-omics methods to examine the biological mechanisms underlying this vulnerability in Small Vulnerable Newborns (SVNs) in LMICs, with the ultimate goal of identifying targeted interventions to reduce morbidity and mortality in this high-risk population. The evidence generated from this project will ultimately help promote healthy pregnancies and the birth of healthy babies. To achieve this goal, three research objectives are proposed: 1. To describe and compare gut microbiota, immune system and breastmilk components in SVNs versus healthy community controls in urban Burkina Faso. 2. To describe and compare the development of the gut microbiota, the immune system and breastmilk components during the first six months of life in SVNs versus healthy community controls in urban Burkina Faso. 3. To investigate the relationship between the composition of the gut microbiota, the immune system and breastmilk components during the first six months of life in SVNs versus healthy community controls in urban Burkina Faso.
Detailed description
The first days and weeks of life are characterized by a truly impressive cascade of biological processes that drive neonatal growth and development-all of which are crucial to preparing the newborn for life outside the womb. First, vaginal delivery exposes neonates to an important natural microbial inoculum from the vaginal microbiota in labor and from the maternal intestinal microbiota at birth. Together, these early colonization events lay the foundation for gut microbiota assembly, inform the arrival of subsequent species through microbial interactions, and dictate infant microbiota maturation. A recent study has shown that a handful of bacteria begin colonizing the infant gut within the first days of life, that gut microbes accumulate gradually over time, and that pioneer strains are retained after a month of life. Whether the gut microbial assembly, maturation, and functional potential differs between SVNs versus healthy, community controls, or is coupled to growth and development, remains unresolved. Secondly, the first days and weeks of life represent a time of heightened vulnerability to infectious disease. Neonatal infections account for a tragic 40% of mortality in children under five years of age. This critical time period is increasingly seen as a key determinant in health over the entire lifespan. A recent study using a high-dimensional, unbiased approach to characterize neonatal immune system development reported a dramatic, purposeful trajectory in the first week of life. While much remains to be explored, what is known is that early microbial colonization is vital to optimal host immune development and protection from disease and that, after birth, the most important determinant of infant gut colonization is breastfeeding. The impacts of preterm birth, low birth weight, or small for gestational age on immune development and function remain enigmatic and the mediating effect of the gut microbiome unknown. Thirdly, neonatal nutrition plays a vital role in the two aforementioned processes-because breastfeeding both initiates tropic priming of the newborn gut and transfers numerous immunological factors to the baby. However, few studies have explored the synergy between neonatal microbiome and immunome development, and even fewer through the lens of newborn nutrition. Moreover, virtually zero studies include an integrated characterization of these processes in the SVN. Evidence suggests that, compared to mothers of full-term neonates, the colostrum from mothers of preterm newborns has higher protein and fat content, free amino acids, sodium, and bioactive milk components including HMOs, cytokines, and lactoferrin. But because few studies have evaluated the association between early milk composition and infant growth and development, it is unclear which components are most imperative for a healthy gut microbiota and a robust immune system, particularly in the SVN. Major advances in systems biology approaches allowing for unbiased, integrated analyses of high-dimensional -omic databases have provided the critical bioinformatic toolkit required to address these questions. Indeed, the ground has never been more fertile for a step-change in commitment to high-impact research on neonatal microbiome and immunome development and the synergy with newborn nutrition.
Interventions
None listed
Sponsors
Study design
Eligibility
Inclusion criteria
* Fundal height between 24 and 27 cm * Woman living in the health zone of Accart-Ville, Colma 1 or Farakan * Woman not planning to give birth or move outside the study area in the first 6 months of the infant's life * Gestational age between 24 weeks 0 completed day and 29 weeks 6 days (ultrasound) * Monofetal pregnancy without visible malformation * Woman agreeing to give her informed consent to participate in the study * Delivery of a live birth * Vaginal birth * Absence of severe infectious pathology, severe pneumopathy or respiratory distress in the neonate * Neonates who did not receive corticosteroids or antibiotics at birth For Small Vulnerable Newborns (SVNs): * Low birth weight: \<2500g; and/or, * Preterm: born between the 34th and 37th week of pregnancy; and/or, * Small for Gestational Age: \<10 percentile of INTERGROWTH-21st birthweight standards. For healthy community controls: * Neonate born after the 37th week of pregnancy; and, * Birth weight \>2500g; and, * ≥10 percentile of INTERGROWTH-21st birthweight standards; and, * Possible match with a SVN neonate already recruited into the study.
Exclusion criteria
* Fundal height \<24 cm or \>27 cm * Woman living outside the sanitary zone of the Accart-Ville, Colma 1 or Farakan * Woman planning to give birth outside the study area or to move from it within the first 6 months of the infants's life * Gestational age \<24 weeks or ≥30 weeks (ultrasound) * Multi-fetal pregnancy * Malformation visible on ultrasound * Cesarean delivery * Neonate with severe infectious disease, severe pneumopathy or respiratory distress * Neonate who received corticosteroids or antibiotics just after birth
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Differential abundances of bacterial genera in the infant gut microbiota | to be assessed at on days 3, 7, 14, 30, 60, 180 of life | Shotgun metagenomic sequencing |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Infant gut microbiota α and β diversity | to be assessed at on days 3, 7, 14, 30, 60, 180 of life | Shotgun metagenomic sequencing |
| Infant plasma immunophenotyping | to be assessed at birth and on days 1, 3, 5, 7, 30, 60 of life | Flow cytometry |
| Infant plasma chemokine and cytokine analyses | to be assessed at birth and on days 1, 3, 5, 7, 30, 60 of life | Electrochemiluminescence and the MSD V-PLEX Human Biomarker 54-Plex Kit |
| Maternal breastmilk component* profiling | on days 3, 7, 14, 30, 60 of life | \*Components include macronutrients, micronutrients, oligosaccharides, growth factors, immunoglobulins, cytokines, metabolites, microbes, and proteins. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Maternal plasma chemokine and cytokine analyses | to be assessed at birth | Electrochemiluminescence and the MSD V-PLEX Human Biomarker 54-Plex Kit |
| Black carbon exposure in umbilical cord arterial blood | to be assessed at birth | White-light generation under femtosecond pulsed illumination |
| Placental DNA adductiomics | to be assessed at birth | Hybrid Quadrupole Orbitrap MS (Q-Exactive™) high-resolution mass spectrometry (HRMS) |
| Relative telomere length (TL) in umbilical cord arterial blood | to be assessed at birth | qPCR |
| Infant untargeted metabolomics on capillary whole blood | to be assessed at birth, on days 1, 3, 5, 7, 14, 30 and 60 of life | Modified Agilent RapidFire 360 sample injector coupled to a high-resolution Agilent 6545B liquid chromatography Quadrupole Time-of-Flight (LC/Q-TOF) next-generation rapid liquid chromatography-mass spectrometry (rLC-MS) |
| Infant untargeted plasma proteomics | to be assessed at birth, on days 1, 3, 5, 7, 14, 30 and 60 of life | Harmonized Orbitrap Exploris™ liquid chromatography-mass spectrometry (LC-MS) |
| Infant multiple mycotoxin profiling on capillary whole blood | to be assessed at birth, on days 7, and 14 of life | Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS) |
| Maternal untargeted capillary whole blood metabolomics | to be assessed at birth | Modified Agilent RapidFire 360 sample injector coupled to a high-resolution Agilent 6545B liquid chromatography Quadrupole Time-of-Flight (LC/Q-TOF) next-generation rapid liquid chromatography-mass spectrometry (rLC-MS) |
| Differential abundance of bacterial populations of pregnant or lactating woman (PLW) fecal microbiota | to be assessed within 28-30 weeks of gestation, within 33-34 weeks of gestation, on days 7, 14, 30, 60 and 180 of life | Shotgun metagenomic sequencing |
| Maternal multiple mycotoxin profiling on capillary whole blood | to be assessed at birth | Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS) |
| PLW shotgun vaginal metagenomics | to be assessed 29-30 weeks of gestation, 33-34 weeks of gestation and at birth | Shotgun metagenomic sequencing |
| Breastmilk volume intake | to be assessed on days 1, 3, 4, 13 and 14 of life | Dose-to-mother deuterium oxide dilution |
| Differential abundances of bacterial genera in the infant gut microbiota | to be assessed at birth and on days 1, 2, 4, 5, 6 of life | Shotgun metagenomic sequencing |
| Infant gut microbiota α and β diversity | to be assessed at birth and on days 1, 2, 4, 5, 6 of life | Shotgun metagenomic sequencing |
| Maternal breastmilk component* profiling | to be assessed at birth and on days 1, 3, 5 of life | Shotgun metagenomic sequencing |
| Vaginal cytokines | to be assessed at 29-30 weeks of gestation | Multi-plex assay |
| Maternal untargeted plasma proteomics | to be assessed at birth | Harmonized Orbitrap Exploris™ liquid chromatography-mass spectrometry (LC-MS) |
| PLW Infant fecal microbiota α and β diversity | to be assessed within 28-30 weeks of gestation, within 33-34 weeks of gestation, on days 7, 14, 30, 60 and 180 of life | Shotgun metagenomic sequencing |
| PLW fecal enteropathogens | to be assessed within 28-30 weeks of gestation, within 33-34 weeks of gestation, on days 30 and 180 of life | TaqMan Array Card (TAC) qPCR to detect 62 infection targets of interest, including viruses, bacteria, protozoa and helminths. |
| Infant fecal enteropathogens | to be assessed within 28-30 weeks of gestation, within 33-34 weeks of gestation, on days 30 and 180 of life | TaqMan Array Card (TAC) qPCR to detect 62 infection targets of interest, including viruses, bacteria, protozoa and helminths. |
| Maternal plasma immunophenotyping | to be assessed at birth | Flow cytometry |
Countries
Burkina Faso